Abstract
The incidence of non-tuberculosis mycobacteria pulmonary disease (NTM-PD) is increasing [1]. Treatment for NTM-PD entails anti-mycobacterial therapy for one-year after sputum conversion [2,3]. Medication intolerance occurs often and makes the management of NTM-PD challenging. As a result, bronchial hygiene without anti-mycobacterial therapy may be appropriate and has been shown to result in sputum conversion in some patients [2,4]. However, current guidelines suggest initiation of anti-mycobacterial therapy, especially in patients with positive acid-fast bacilli sputum smears and/or cavitary disease [5].
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call